αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model
Marine Drugs · 2024
DOI: 10.3390/md22010049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2024. Verfasst von Huanbai Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China. Hauptthemen laut MEDLINE: Conotoxins, Neuralgia, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Key R & D Program of China, Guangxi Science and Technology Base & Talents Fund.
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting painful neuropathy that occurs commonly during cancer management, which often leads to the discontinuation of medication. Previous studies suggest that the α9α10 nicotinic acetylcholine receptor (nAChR)-specific antagonist αO-conotoxin GeXIVA[1,2] is effective in CIPN models; however, the related mechanisms remain unclear. Here, we analyzed the preventive effect of GeXIVA[1,2] on neuropathic pain in the long-term oxaliplatin injection-induced CIPN model. At the end of treatment, lumbar (L4-L6) spinal cord was extracted, and RNA sequencing and bioinformatic analysis were performed to investigate the potential genes and pathways related to CIPN and GeXIVA[1,2]. GeXIVA[1,2] inhibited the development of mechanical allodynia induced by chronic oxaliplatin treatment. Repeated injections of GeXIVA[1,2] for 3 weeks had no effect on the mice’s normal pain threshold or locomotor activity and anxiety-like behavior, as evaluated in the open field test (OFT) and elevated plus maze (EPM). Our RNA sequencing results identified 209 differentially expressed genes (DEGs) in the CIPN model, and simultaneously injecting GeXIVA[1,2] with oxaliplatin altered 53 of the identified DEGs. These reverted genes were significantly enriched in immune-related pathways represented by the cytokine–cytokine receptor interaction pathway. Our findings suggest that GeXIVA[1,2] could be a potential therapeutic compound for chronic oxaliplatin-induced CIPN management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.
- Department of Biology and Department of Psychiatry, University of Utah, Salt Lake City, UT 84112, USA.
- George E. Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84108, USA.
ORCID-Profile: Sulan Luo
Förderung
- NIGMS NIH HHS
- National Key R & D Program of China
- Guangxi Science and Technology Base & Talents Fund
- National Natural Science Foundation of China
- 111 Project
- U.S. National Institutes of Health
Zitieren
APA
Wang, H., Li, X., Qiao, Y., Wang, M., Wang, W., McIntosh, J. M., Zhangsun, D., & Luo, S. (2024). αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model. Marine Drugs. https://doi.org/10.3390/md22010049
Vancouver
Wang H, Li X, Qiao Y, Wang M, Wang W, McIntosh JM, et al. αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model. Marine Drugs. 2024. doi:10.3390/md22010049
BibTeX
@article{Wang2024,
author = {Wang, Huanbai and Li, Xiaodan and Qiao, Yamin and Wang, Meiting and Wang, Wen and McIntosh, J Michael and Zhangsun, Dongting and Luo, Sulan},
title = {αO-Conotoxin GeXIVA[1,2] Reduced Neuropathic Pain and Changed Gene Expression in Chronic Oxaliplatin-Induced Neuropathy Mice Model},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22010049}
}
EUVIMED